Bristol-Myers Squibb Company

Bristol-Myers Squibb Company(BMY)の株式分析

$59.280

+2.733 (+4.61%)終値時点

Loading chart…
高値
59.385
始値
56.810
出来高加重平均価格
58.41
出来高
14.05M
時価総額
84.14B
安値
56.580
売買代金
820.96M
EV/EBITDA(TTM)
7.83

Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development, and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Orencia (abatacept), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Breyanzi (lisocabtagene maraleucel), Opdualag (nivolumab and relatlimab-rmbw), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), Sotyktu (deucravacitinib), Krazati (adagrasib), and Cobenfy (xanomeline and trospium chloride). Its other growth products include Augtyro, Onureg, Inrebic, Nulojix, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension).

www.bms.com

AI分析 of Bristol-Myers Squibb Company (BMY)

買い

Bristol-Myers Squibb is a good buy right now due to its current price of $59.12, which is below the analyst price target of $66 from BofA. Additionally, the company has a strong gross margin of 68.03% reported in Q2 2026, indicating solid profitability. However, the main risk is the declining revenue trend, with a slight decrease of 0.2% year-over-year reported for FY 2025.

アナリスト評価(22)

-5.77% 下落余地
中立
9 買い
11 中立
2 売り
現在: 59.28
安値
37.00
平均
55.86
高値
68.00

Jefferies

2026-10-12

目標株価

$76

買い

William Blair

2026-10-12

目標株価

—

Market Perform

BofA

2026-10-09

目標株価

$66

買い

Cantor Fitzgerald

2026-10-08

目標株価

$53

中立

Morgan Stanley

2026-10-07

目標株価

$41

アンダーウェイト

バリュエーション指標

Bristol-Myers Squibb Company(BMY)の現在の予想PERは9.36で、5年平均は11.38です。

予想PER

適正
5年平均 P/E
11.38
現在のP/E
9.36
割高
24.94
割安
-2.19

予想EV/EBITDA

適正
5年平均 EV/EBITDA
10.20
現在のEV/EBITDA
7.83
割高
14.39
割安
6.01

予想PSR

適正
5年平均 P/S
2.67
現在のP/S
2.50
割高
3.19
割安
2.16

Alphio AI による BMY の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%BMY

$44.66

シナリオ価格

基

基本

基本 · 50%BMY

$40.66

シナリオ価格

弱

弱気

弱気 · 25%BMY

$35.77

シナリオ価格

BMY を保有するクジラ

T

Turtle Creek Management, LLC

+ を保有BMY

+21.39%

3か月リターン

C

Cbus Industry Superannuation Fund

+ を保有BMY

+9.20%

3か月リターン

D

DWS Investment Management Americas, Inc.

+ を保有BMY

+8.52%

3か月リターン

N

Nan Shan Life Insurance Co., Ltd.

+ を保有BMY

+8.14%

3か月リターン

M

Martingale Asset Management, L.P.

+ を保有BMY

+7.91%

3か月リターン

O

Osmosis Investment Management UK Limited

+ を保有BMY

+7.38%

3か月リターン

イベントタイムライン

2026-10-12 (ET)

14:00:00

RBC Analyst Calls Bristol Myers Drug Results Positive

09:00:00

S&P 500 Futures Mixed as Oil Prices Rise

07:00:00

Bristol Myers Squibb Announces Phase 3 Trial Results for Admilparant

07:00:00

Bristol Myers Squibb Announces Positive ACTION-1 Trial Results

2026-10-08 (ET)

07:30:00

Bristol Myers Announces Positive Phase 3 Results for Zenbexus

ニュース

BMY のよくある質問 — Alphio AI が回答

Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development, and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Orencia (abatacept), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Breyanzi (lisocabtagene maraleucel), Opdualag (nivolumab and relatlimab-rmbw), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), Sotyktu (deucravacitinib), Krazati (adagrasib), and Cobenfy (xanomeline and trospium chloride). Its other growth products include Augtyro, Onureg, Inrebic, Nulojix, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Bristol-Myers Squibb is a good buy right now due to its current price of $59.12, which is below the analyst price target of $66 from BofA. Additionally, the company has a strong gross margin of 68.03% reported in Q2 2026, indicating solid profitability. However, the main risk is the declining revenue trend, with a slight decrease of 0.2% year-over-year reported for FY 2025.

22 analysts cover BMY: 9 rate it Buy, 11 Hold and 2 Sell. The average price target is 55.86.

コミュニティ

もっと見る ↗
molten_vortex2026/9/26

Innovation Is Driving a New Bull Market in Biotech. 16 Ways to Play It, From Our Roundtable Experts. Biotechnology stocks are soaring this year as medical advances and merger activity rekindle investor interest. More gains lie ahead, our healthcare panel says. A tidal wave of innovation in biotechnology is improving patient outcomes, transforming the industry's prospects, and lifting long-suffering biotech shares. Spurred by therapeutic breakthroughs and new-product launches, investors have bid up the iShares Biotechnology, or IBB, by 24% this year, while the State Street SPDR S&P Biotech ETF, or XBI, has risen 28%, more than twice the gain of the S&P 500. Large pharmaceutical companies are also paying attention. They have been striking licensing deals with smaller biotechs and scooping up whole companies in a bid to rebuild their pipelines and replace blockbuster drugs facing patent expirations. $MRNA $MRK $RVMD $BMY $SMMT

もっと見る
RektEddy2026/9/15

$PGR $SYK $BMY Many people enter the crypto space chasing quick profits, but real, consistent success is built on knowledge, discipline, and the right guidance. That’s where having a reliable mentor makes all the difference. Craig has played a key role in helping me understand the markets with more clarity and confidence. His approach to trading goes beyond signals, it’s about building structure, managing risk, and staying focused on long-term growth. With his guidance and his YouTube videos, I’ve been able to make smarter decisions, avoid emotional trading, and stay consistent even in volatile conditions. The shift in mindset alone has been a game changer.

もっと見る
登録またはログインして議論に参加

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める